Pre-transplant utilization of sorafenib is not associated with increased complications after liver transplantation

Transplant International

Volumn 26, Issue 7, 2013, Pages 734-739

  Frenette, Catherine T ^a   Boktour, Maha ^b   Burroughs, Sherilyn G ^b   Kaseb, Ahmed ^c   Aloia, Thomas A ^c   Galati, Joseph ^d   Gaber, Ahmed O ^b   Monsour, Howard ^b   Ghobrial, Rafik M ^b  

^a SCRIPPS CLINIC   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d Dermatological Association of Texas   (United States)

Author keywords

hepatocellular carcinoma; liver cancer; orthotopic liver transplantation; sorafenib; surgical complications

Indexed keywords

SORAFENIB;

ADULT; ARTICLE; BACTEREMIA; BILE LEAKAGE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CHOLESTASIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INCISIONAL HERNIA; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER NODULE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; POST TREATMENT SURVIVAL; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; REOPERATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURGICAL INFECTION; SURGICAL PATIENT; SURGICAL RISK; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84879006659     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12117     Document Type: Article

References (19)

1. Parkin DM, Bray F, Ferlay J, et al,. Estimating the world cancer burden: GLOBOCAN 2001. Int J Cancer 2001; 94: 153.
2. Altekruse S, McGlynn K, Reichman M,. Hepatocellular carcinoma incidence, morality, and survival trends in the Unites States from 1975 to 2005. J Clin Oncol 2009; 27: 1485.
3. Mazzaferro V, Regalia E, Doci R, et al,. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 344: 693.
4. Guiteau JJ, Cotton RT, Washburn WK, et al,. An early regional experience with expansion of Milan criteria for liver transplant recipients. Am J Transplant 2010; 10: 2092.
5. Llovet JM, Ricci S, Mazzaferro V, et al,. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378.
6. Saidi RF, Shah SA, Rawson AP, Grossman ST, Piperdi B, Bozorgzadeh A,. Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience. Transplant Proc 2010; 42: 4582.
7. Vitale A, Volk ML, Pastorelli D, et al,. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. Hepatology 2010; 51: 165.
8. Vagefi PA, Hirose R,. Downstaging of hepatocellular carcinoma prior to liver transplant: is there a role for adjuvant sorafenib in locoregional therapy? J Gastrointest Cancer 2010; 41: 217.
9. Wiesner R, Edwards E, Freeman R, et al,. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterol 2003; 124: 91.
10. Truesdale AE, Caldwell SH, Shah NL, et al,. Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant. Transpl Int 2011; 24: 991.
11. Masouka HC, Rosen CB,. Liver transplantation for hepatocellular carcinoma: expanding frontiers and building bridges. Clin Liver Dis 2011; 15: 385.
12. Llovet JM, Fuster J, Bruix J,. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30: 1434.
13. Yao FY, Bass NM, Nikolai B, et al,. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002; 8: 873.
14. Yamashiki N, Gaynor JJ, Kato T, et al,. Predictors of delisting owing to tumor progression in liver transplant candidates with hepatocellular carcinoma. Am J Transplant 2004; 4: 774.
15. Jang JW, Choi JY, Bae SH, et al,. The best candidates for transarterial chemoembolization in patients with hepatocellular carcinoma awaiting liver transplantation: a cohort-based characterization of dropout times. Aliment Pharmacol Ther 2007; 26: 87.
16. Roberts JP, Venook A, Kerlan R, Yao F,. Hepatocellular carcinoma: ablate and wait versus rapid transplantation. Liver Transpl 2010; 16: 925.
17. Lencioni R, Llovet JM, Han G, Tak W-Y, Yang J,. Sorafenib or placebo in combination with transarterial chemoembolization with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, double-blind SPACE trial. J Clin Oncol 2012; 30 (suppl 4). abstr LBA154.
18. Hora C, Romangue P, Dufour JF,. Effect of sorafenib on murine liver regeneration. Hepatol 2011; 53: 577.
19. Cowey CL, Amin C, Pruthi RS, et al,. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol 2010; 28: 1502.